Press Release: Integra LifeSciences Reports Third -4-
Press Release: Integra LifeSciences Reports Third -4-
(1) Acquisition, divestiture and integration-related charges are associated with the Codman Neurosurgery, Arkis Biosciences, Rebound Therapeutics and ACell acquisitions and the divestiture of Extremity Orthopedics and includes banking, legal, consulting, systems, and other income and expenses.
(1)收购、剥离和整合相关费用与Codman神经外科、Arkis生物科学、反弹治疗和ACell收购以及剥离Extremity Orthopedics有关，包括银行、法律、咨询、系统和其他收入和支出。
(2) Upon adoption of ASU No. 2020-06, the Company will no longer incur non-cash interest expense for the amortization of debt discount.
(2)采用ASU第2020-06号文件后，本公司将不再发生债务折价摊销的非现金利息支出。
RECONCILIATION OF NON-GAAP ADJUSTMENTS - GAAP NET INCOME TO MEASURES OF ADJUSTED NET INCOME AND ADJUSTED EARNINGS PER SHARE
非GAAP调整-GAAP净收入与调整后净收入和调整后每股收益的衡量标准
(UNAUDITED)
(未经审计)
(In thousands, except per share amounts)
(单位为千，每股除外)
Three Months Ended September 30,
------------------------------------------
2021 2020
-------------------- --------------------
GAAP net income 43,229 32,337
Non-GAAP adjustments:
Structural optimization charges 6,696 4,543
Acquisition, divestiture and
integration-related charges(1) 2,637 7,148
COVID-19 related charges -- (193)
EU Medical Device Regulation
charges 7,077 2,399
Discontinued product lines
charges 23 999
Intangible asset amortization
expense 20,248 20,180
Expenses related to debt
refinancing -- 3,428
Convertible debt non-cash
interest (2) -- 4,295
Estimated income tax impact from
adjustments and other items (6,853) (7,433)
---------------- ----------------
Total of non-GAAP
adjustments 29,828 35,366
---------------- ----------------
Adjusted net income $ 73,058 $ 67,703
------------ ------------
Adjusted diluted net income per
share $ 0.86 $ 0.80
Weighted average common shares
outstanding for diluted net
income per share 85,447 84,752
截至9月30日的三个月， ------------------------------------------ 2021 2020 -------------------- -------------------- 公认会计准则净收益43,229 32,337非GAAP调整：结构优化费用6696 4543收购、剥离和与融合有关的收费(1)2637 7148新冠肺炎相关收费--(193)欧盟医疗器械法规收费7,077,399停产产品线收费23999无形资产摊销费用20,248 20,180与债务有关的费用再融资--3,428可转换债务非现金利息(2)--4,295估计所得税的影响来自调整和其他项目(6853)(7433) ---------------- ---------------- 非GAAP合计调整29,828 35,366 ---------------- ---------------- 调整后净收入73,058美元67,703美元 ------------ ------------ 调整后稀释净收入每股0.86美元0.80美元加权平均普通股未清偿稀释净额每股收益85,447 84,752
(1) Acquisition, divestiture and integration-related charges are associated with the Codman Neurosurgery, Arkis Biosciences, Rebound Therapeutics and ACell acquisitions and the divestiture of Extremity Orthopedics and includes banking, legal, consulting, systems, and other income and expenses.
(1)收购、剥离和整合相关费用与Codman神经外科、Arkis生物科学、反弹治疗和ACell收购以及剥离Extremity Orthopedics有关，包括银行、法律、咨询、系统和其他收入和支出。
(2) Upon adoption of ASU No. 2020-06, the Company will no longer incur non-cash interest expense for the amortization of debt discount.
(2)采用ASU第2020-06号文件后，本公司将不再发生债务折价摊销的非现金利息支出。
CONDENSED BALANCE SHEET DATA
浓缩资产负债表数据
(UNAUDITED)
(未经审计)
(In thousands)
(单位：千)
September 30, December 31,
2021 2020
--------------- ----------------
Cash and cash equivalents $ 470,231 $ 470,166
Trade accounts receivable, net 222,232 225,532
Inventories, net 327,167 310,117
Current and long-term borrowing under
senior credit facility 868,736 967,137
Borrowings under securitization
facility 111,700 112,500
Long-term convertible securities 563,697 474,834
Stockholders' equity $ 1,631,687 $ 1,514,867
----------- ----------
九月三十日，十二月三十一日， 2021 2020 --------------- ---------------- 现金及现金等价物$470,231$470,166应收贸易账款，净额222,232 225,532库存，净额327,167 310,117项下的经常和长期借款高级信贷安排868,736 967,137证券化下的借款设施111,700 112,500长期可转换证券563,697,474,834股东权益$1,631,687$1,514,867 ----------- ----------
CONDENSED STATEMENT OF CASH FLOWS
简明现金流量表
(UNAUDITED)
(未经审计)
(In thousands)
(单位：千)
Nine Months Ended September 30,
2021 2020
--------------------- ----------------
Net cash provided by operating
activities $ 243,150 $ 123,570
Net cash used in investing
activities (133,958) (32,152)
Net cash (used) provided by
financing activities (98,747) 100,403
Effect of exchange rate changes
on cash and cash equivalents (10,380) 5,547
----------------- -------------
Net increase (decrease) in cash
and cash equivalents $ 65 $ 197,368
------------- ------------
截至9月30日的9个月， 2021 2020 --------------------- ---------------- 运营提供的净现金活动$243,150$123,570用于投资的净现金活动(133,958)(32,152)提供的净现金(已用)融资活动(98,747)100,403汇率变动的影响关于现金和现金等价物(10,380)5,547 ----------------- ------------- 现金净增(减)和现金等价物$65$197,368 ------------- ------------
RECONCILIATION OF NON-GAAP ADJUSTMENTS - GAAP OPERATING CASH FLOW TO
非GAAP调整的对账-GAAP营业现金流
MEASURES OF FREE CASH FLOW AND ADJUSTED FREE CASH FLOW CONVERSION
自由现金流量和调整后自由现金流量换算的计量
(UNAUDITED)
(未经审计)
(In thousands)
(单位：千)
Three Months Ended September 30,
2021 2020
---------------------- -----------------
Net cash provided by operating
activities $ 82,778 $ 69,643
------------ ---- ----------- ---
Purchases of property and
equipment (7,286) (6,727)
---------------- --- ------------
Free cash flow 75,492 62,916
Adjusted net income(1) $ 73,058 $ 67,703
------------ ---- ----------- ---
Adjusted free cash flow
conversion 103.3% 92.9%
Twelve Months Ended September 30,
2021 2020
---------------------- -----------------
Net cash provided by operating
activities $ 323,414 $ 212,757
Purchases of property and
equipment (29,023) (52,656)
Adjusted free cash flow 294,391 160,101
Adjusted net income(1) $ 270,780 $ 196,266
------------ ---- ----------- ---
Adjusted free cash flow
conversion 108.7% 81.6%
截至9月30日的三个月， 2021 2020 ---------------------- ----------------- 运营提供的净现金活动$82,778$69,643 ------------ ---- ----------- --- 购买物业及设备(7286)(6727) ---------------- --- ------------ 自由现金流75,492 62,916调整后净收入(1)$73,058$67,703 ------------ ---- ----------- --- 调整后的自由现金流转换率103.3%92.9%截至9月30日的12个月， 2021 2020 ---------------------- ----------------- 运营提供的净现金活动$323,414$212,757购买物业及设备(29,023)(52,656)调整后自由现金流294,391 160,101调整后净收入(1)270,780美元196,266美元 ------------ ---- ----------- --- 调整后的自由现金流转换率108.7%81.6%
(1) Adjusted net income for quarters ended September 30, 2020 and 2021 are reconciled above. Adjusted net income for remaining quarters in the trailing twelve months calculation have been previously reconciled and are publicly available in the Quarterly Earnings Call Presentations on our website at investor.integralife.com under Events & Presentations.
(1)截至2020年9月30日和2021年9月30日的季度调整后净收入如上所示。在过去12个月的计算中，其余季度的调整后净收入以前已经过调整，并在我们的网站Investor.Integralife.com上的活动和演示下的季度收益电话会议上公开提供。
The Company calculates adjusted free cash flow conversion by dividing its free cash flow by adjusted net income. The Company believes this measure is useful in evaluating the significance of the cash special charges in its adjusted earnings measures.
该公司通过将其自由现金流除以调整后的净收入来计算调整后的自由现金流转换。该公司相信，这一衡量标准有助于评估现金特别费用在其调整后收益衡量标准中的重要性。
译文内容由第三方软件翻译。